Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$10.93
$4.51
$20.20
$236.61M0.4162,237 shs171,500 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+8.7%
$0.01
$0.01
$0.02
$1.19M-0.92430,968 shs205,255 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.12
-1.3%
$0.73
$0.28
$2.45
$403.06M1.139.85 million shs2.49 million shs
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$1.16
$0.98
$4.95
$69.47M2.34396,682 shs296,500 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$9.52
-3.1%
$10.13
$8.58
$25.07
$819.20M0.71.85 million shs475,935 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00%0.00%0.00%0.00%0.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-8.00%-8.00%-8.00%-3.16%-8.00%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+5.61%+24.18%+61.18%+120.79%-30.67%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+6.28%+5.86%-12.63%-12.01%-56.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.6354 of 5 stars
0.03.00.04.80.00.00.0
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.7867 of 5 stars
3.23.00.00.02.32.50.6
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.3599 of 5 stars
3.51.00.04.42.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67228.85% Upside
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00
N/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.90
Moderate Buy$34.30260.29% Upside

Current Analyst Ratings Breakdown

Latest LXRX, SNDX, EVFM, ADRO, and OSMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$17.26M0.00N/AN/A$4.07 per share0.00
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.21M12.91N/AN/A$0.40 per share2.79
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$177.88M0.00N/A1.00$1.50 per share0.00
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M34.59N/AN/A$3.38 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)

Latest LXRX, SNDX, EVFM, ADRO, and OSMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.99N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/5/2025Q1 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/A
8.91
8.91
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/A
0.43
0.42
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
1.53
5.80
5.75
CompanyEmployeesShares OutstandingFree FloatOptionable
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
15216.21 millionN/AOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
30262.59 million59.32 millionNot Optionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.05 million82.52 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aduro Biotech stock logo

Aduro Biotech NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.01 +0.00 (+8.70%)
As of 01:00 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.12 -0.02 (-1.33%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Osmotica Pharmaceuticals stock logo

Osmotica Pharmaceuticals NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$9.52 -0.30 (-3.05%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.